MYC is a well-established BRD4 target; however, the re-introduction of MYC failed to rescue the growth suppression by BET inhibitors in melanoma, even with the combination of the cyclin-dependent kinase (CKD) inhibitor therapy and p21 knockdown 7. Here, BRD4 is linked to melanoma.